<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121007">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01894971</url>
  </required_header>
  <id_info>
    <org_study_id>2013-06-25</org_study_id>
    <nct_id>NCT01894971</nct_id>
  </id_info>
  <brief_title>The Effect of Ligasure® to Destroy Cornual Portion of Fallopian Tube</brief_title>
  <official_title>The Effect of Thermal Damage of Ligasure® to Destroy Cornual Portion of Fallopian Tube Tissue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-center prospective randomized trial to evaluate the effect of thermal damage of
      Ligasure® to destroy cornual portion of fallopian tube tisse.

      Right of Left side of fallpian tube is randomized and coagulated one more time than other
      side before cut off. The pathologist evaluate the amount of fallopian tube tissue left at
      both cornual portion of cut off specimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When investigators perform salpingectomy, both side of cornual portion of the uterus are
      coagulated by Ligasure®. The randomized, the same word selected side of the fallopian tube
      is coagulated one more time at the cornual portion than unselected other side of fallopian
      tube. Hypothesis is that the side selected and coagulated twice would have less fallopian
      tube tisse left at fianl pathology than the side only once coagulated by Ligasure®.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Remnant fallopian tube tissue after coagulation wiht Ligasure®</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Recruiting</condition>
  <arm_group>
    <arm_group_label>twice coagulated side of fallopian tube</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice coagulated side of fallopian tube once coagulated sied of fallopian tube</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Effect of Ligasure® to Destroy Cornual Portion of Fallopian Tube</intervention_name>
    <arm_group_label>twice coagulated side of fallopian tube</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female 35-50

          -  premenopausal

          -  plan to perform hysterectomy

        Exclusion Criteria:

          -  disease in fallopian tube before surgery

          -  has history of pelvic inflammatory disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae Joong Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tae Joong Kim, MD</last_name>
    <phone>82-2-3410-3547</phone>
    <email>tj28.kim@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae Joong Kim, MD</last_name>
      <phone>82-2-3410-3547</phone>
      <email>tj28.kim@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jin Young Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 3, 2013</lastchanged_date>
  <firstreceived_date>June 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Tae-Joong Kim</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
